science π§ Glioma treatment focus shifts to tumor environment
Glioma prognosis remains poor despite standard multimodal therapy, which rarely exceeds 15 to 18 months survival. This resistance stems from the tumor microenvironment (TME) ecosystem, involving microglia and macrophages that cause immunosuppression. Neurons also form synapses with glioma cells, driving growth by releasing neurotransmitters like glutamate. Reactive astrocytes and oligodendrocyte lineage cells further support tumor invasion and evasion. Future therapy will focus on disrupting this entire ecosystem, not just killing cancer cells. π§